Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib vs Ibrutinib + Rituximab in Relapsed CLL
NCT02007044Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2013
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, rituximab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2013; status: active, not recruiting.
02
Drugs
ibrutinibrituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT02007044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007044.